AbbVie/Genmab lymphoma drug combo cut progression or death risk by 51% in trial
AbbVie Inc and Genmab A/S said their combination treatment for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) reduced the risk of disease progression or death by 51% compared with R-CHOP alone. The study tested epcoritamab in combination with R-CHOP in newly diagnosed patients with DLBCL.